118 related articles for article (PubMed ID: 23234235)
41. Bioactivity and toxicity studies of amphotericin B incorporated in liquid crystals.
Chuealee R; Aramwit P; Noipha K; Srichana T
Eur J Pharm Sci; 2011 Jul; 43(4):308-17. PubMed ID: 21616148
[TBL] [Abstract][Full Text] [Related]
42. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
43. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
[TBL] [Abstract][Full Text] [Related]
44. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
[TBL] [Abstract][Full Text] [Related]
45. PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome.
Van de Ven H; Paulussen C; Feijens PB; Matheeussen A; Rombaut P; Kayaert P; Van den Mooter G; Weyenberg W; Cos P; Maes L; Ludwig A
J Control Release; 2012 Aug; 161(3):795-803. PubMed ID: 22641062
[TBL] [Abstract][Full Text] [Related]
46. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.
Corware K; Harris D; Teo I; Rogers M; Naresh K; Müller I; Shaunak S
Biomaterials; 2011 Nov; 32(31):8029-39. PubMed ID: 21807409
[TBL] [Abstract][Full Text] [Related]
47. Potent plasmodicidal activity of a heat-induced reformulation of deoxycholate-amphotericin B (Fungizone) against Plasmodium falciparum.
Hatabu T; Takada T; Taguchi N; Suzuki M; Sato K; Kano S
Antimicrob Agents Chemother; 2005 Feb; 49(2):493-6. PubMed ID: 15673723
[TBL] [Abstract][Full Text] [Related]
48. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.
Chattopadhyay A; Jafurulla M
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):7-12. PubMed ID: 22100811
[TBL] [Abstract][Full Text] [Related]
49. Coalition of Biological Agent (Melatonin) With Chemotherapeutic Agent (Amphotericin B) for Combating Visceral Leishmaniasis via Oral Administration of Modified Solid Lipid Nanoparticles.
Parvez S; Yadagiri G; Arora K; Javaid A; Kushwaha AK; Singh OP; Sundar S; Mudavath SL
ACS Biomater Sci Eng; 2023 Jun; 9(6):2902-2910. PubMed ID: 34463477
[TBL] [Abstract][Full Text] [Related]
50. Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis.
Kumar R; Pandey K; Sahoo GC; Das S; Das V; Topno RK; Das P
Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():1465-1471. PubMed ID: 28415438
[TBL] [Abstract][Full Text] [Related]
51. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity.
Adams ML; Andes DR; Kwon GS
Biomacromolecules; 2003; 4(3):750-7. PubMed ID: 12741794
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of Antileishmanial Activity Employing Conventional and Solid Lipid Nanoparticles of Amphotericin B on Leishmania major In Vitro and In Vivo.
Soltani S; Mojiri-Forushani H; Soltani S; Kahvaz MS; Foroutan M
Infect Disord Drug Targets; 2020; 20(6):822-827. PubMed ID: 31613731
[TBL] [Abstract][Full Text] [Related]
53. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B.
Ménez C; Legrand P; Rosilio V; Lesieur S; Barratt G
Mol Pharm; 2007; 4(2):281-8. PubMed ID: 17397240
[TBL] [Abstract][Full Text] [Related]
54. Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres.
Veerareddy PR; Vobalaboina V; Ali N
J Drug Target; 2009 Feb; 17(2):140-7. PubMed ID: 19089691
[TBL] [Abstract][Full Text] [Related]
55. Development, Characterization, and In Vitro Biological Performance of Amphotericin B and Terbinafine Microemulsions Against Leishmania major.
Baharvandi Z; Salimi A; Arjmand R; Jelowdar A; Rafiei A
Curr Microbiol; 2022 Nov; 79(12):386. PubMed ID: 36329207
[TBL] [Abstract][Full Text] [Related]
56. Development of polyion complex micelles for encapsulating and delivering amphotericin B.
Wang CH; Wang WT; Hsiue GH
Biomaterials; 2009 Jul; 30(19):3352-8. PubMed ID: 19299011
[TBL] [Abstract][Full Text] [Related]
57. High purity amphotericin B.
Cleary JD; Chapman SW; Swiatlo E; Kramer R
J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
[TBL] [Abstract][Full Text] [Related]
58. Exploring the Role of Nanoparticles in Amphotericin B Delivery.
Zaioncz S; Khalil NM; Mainardes RM
Curr Pharm Des; 2017; 23(3):509-521. PubMed ID: 27799043
[TBL] [Abstract][Full Text] [Related]
59. Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy.
Gupta PK; Jaiswal AK; Asthana S; Teja B V; Shukla P; Shukla M; Sagar N; Dube A; Rath SK; Mishra PR
Br J Pharmacol; 2015 Jul; 172(14):3596-610. PubMed ID: 25825339
[TBL] [Abstract][Full Text] [Related]
60. Decrease in Fungizone toxicity induced by the use of Lipofundin as a dilutent: an in vitro study.
de Araújo IB; Damasceno BP; de Medeiros TM; Soares LA; do Egito ES
Curr Drug Deliv; 2005 Apr; 2(2):199-205. PubMed ID: 16305421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
